Our laboratory investigates the mechanisms underlying TRAIL resistance with aims at identifying biomarkers for prediction of tumor resistance to the targeted therapies and also identifying novel molecular targets for therapeutic intervention for improved anticancer efficacy [12, 13, 29, 30, 50]. The gene discussed is TNFSF10; the disease is neoplasm.